160005-43-6

Basic information

• Product Name: (4-Bromo-thiophen-2-yl)-acetonitrile
• Synonyms: (4-Bromo-thiophen-2-yl)-acetonitrile
• CAS NO: 160005-43-6
• Molecular Formula: C₆H₄BrNS
• Molecular Weight: 202.07166
• Mol File: 160005-43-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 289.3°C at 760 mmHg
• Flash Point: 128.8°C
• Appearance: /
• Density: 1.665g/cm³
• Vapor Pressure: 0.00222mmHg at 25°C
• Refractive Index: 1.605
• CAS DataBase Reference: (4-Bromo-thiophen-2-yl)-acetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: (4-Bromo-thiophen-2-yl)-acetonitrile(160005-43-6)
• EPA Substance Registry System: (4-Bromo-thiophen-2-yl)-acetonitrile(160005-43-6)

Safety Data

• HazardClass: IRRITANT, IRRITANT-HARMFUL
• Hazardous Substances Data: 160005-43-6(Hazardous Substances Data)

Usage

Uses

2-(4-bromothiophen-2-yl)acetonitrile is used in preparation of fused dihydropyridinone derivatives as janus kinase (JAK) inhibitors for prevention or treatment of autoimmune diseases.

InChI:InChI=1/C6H4BrNS/c7-5-3-6(1-2-8)9-4-5/h3-4H,1H2

Upstream product

• 79757-77-0 (4-bromothiophen-2-yl)methanol 
• 18791-75-8 4-Bromothiophen-2-aldehyde 
• 170859-70-8 4-bromo-2-(chloromethyl)thiophene 
• 151-50-8 potassium cyanide 

Downstream Products

• 917772-62-4 C₂₃H₃₁BrN₂O₄SSi 
• 1192479-41-6 C₂₃H₂₇BrN₄O₃S 
• 917772-60-2 C₁₇H₁₆BrNO₄S 
• 917772-61-3 C₁₈H₁₈BrNO₄S 
• 1192479-39-2 C₁₈H₁₈BrNO₄S*ClH 

Relevant articles and documents

Rapid and Simple Access to α-(Hetero)arylacetonitriles from Gem-Difluoroalkenes

A scalable cyanation of gem-difluoroalkenes to (hetero)arylacetonitrile derivatives was developed. This strategy features mild reaction conditions, excellent yields, wide substrate scope, and broad functional group tolerance. Significantly, in this reacti

Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: Conformational constraint to favor a bioactive conformation

On the basis of our observation that the biaryl substituent of iminopyrimidinone 7 must be in a pseudoaxial conformation to occupy the contiguous S1-S3 subsites of BACE1, we have designed a novel fused bicyclic iminopyrimidinone scaffold intended to favor this bioactive conformation. Strategic incorporation of a nitrogen atom in the new constrained ring allowed us to develop SAR around the S2′ binding pocket and ultimately resulted in analogues with low nanomolar potency for BACE1. In particular, optimization of the prime side substituent led to major improvements in potency by displacement of two conserved water molecules from a region near S2′. Further optimization of the pharmacokinetic properties of this fused pyrrolidine series, in conjunction with facile access to a rat pharmacodynamic model, led to identification of compound 43, which is an orally active, brain penetrant inhibitor that reduces Aβ40 in the plasma, CSF, and cortex of rats in a dose-dependent manner.

TRIAZOLE DERIVATIVE OR SALT THEREOF

[Problem] To provide a compound which may be used in treating diseases in which 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is concerned, especially diabetes and insulin resistance. [Means for Solution] It was found that a triazole derivative or a pharmaceutically acceptable salt thereof, in which the 3-position of triazole ring is substituted with a trisubstituted methyl group and the 5-position is substituted with a lower alkyl, cycloalkyl or the like, has a strong 11β-HSD1-inhibitory activity. In addition, since the triazole derivative of the present invention shows excellent blood glucose-lowering action, it may be used in the treatment of diabetes and insulin resistance.